A Cell Built From Scratch Just Completed Its Full Life Cycle. Nobody Can Agree If It’s Alive

Watch the microscopy footage and you would swear you were looking at biology. A green blob feeds, swells, then pinches itself in two, one cell becoming two, the way living things have done for something like four billion years. Except this blob was never born. Every part of it was assembled from non-living chemicals on a bench at the University of Minnesota. Its makers call it SpudCell, and it has just run the complete set of moves biology teachers reserve for the living: it eats, it grows, it copies its own DNA, it divides.

But the people who built it still can’t quite agree on the right verb for what it is.

“This is likely the most exciting project I’ve ever worked on,” says Kate Adamala, the associate professor whose team, alongside that of her colleague Aaron Engelhart, put SpudCell together. For years the idea of a fully synthetic organism sat where warp drives sit, filed under science fiction. You could copy any one trait of life in isolation, sure, but stitching the whole repertoire into a single self-made package was another matter. “We’ve replicated in chemistry what only used to be possible in biology,” she says, and goes further, arguing the work proves life’s most basic functions “do not need a mysterious magical spark.”

Strip away the wonder and the engineering is properly clever. Take division, a stubborn bottleneck for the field.

Natural cells split using an internal scaffold called a cytoskeleton, a bit of machinery fiendishly hard to rebuild from parts. SpudCell doesn’t bother with one. Instead it uses proteins that crowd together on the membrane’s surface, packing tighter and tighter until the sheer mechanical stress makes the membrane split. A controlled structural failure, engineered on purpose. And the genome running the show is startlingly lean: roughly 90 kilobase pairs, spread across seven separate rings of DNA rather than one tidy chromosome. Your own genome, for comparison, runs to about 3 million kbp, and biologists had reckoned the floor for a living cell sat around 113 kbp. SpudCell squeaks in under that.

Perhaps the most unsettling detail is what happened when the team let it compete. A genetic tweak cranked up production of a key protein; the altered cells grew faster, made more offspring, and after just five generations had elbowed the originals aside. Starve the culture, and the winner’s edge only sharpened. That, in a dish of manufactured chemistry, is natural selection at work.

The Governance Machinery Was Already Turning

Here’s the part that reads almost like choreography. Weeks before the SpudCell paper landed, the US National Academies published a hefty report on exactly this technology, and Adamala had sat on the committee that wrote it. Its co-chair, synthetic biologist Peter Carr of RTX BBN Technologies, had spent the better part of a year wrestling with the very question SpudCell now forces open. Are these things alive? “Those questions are simple and complicated all at the same time,” he says.

Carr’s committee sketched a continuum. At one end, synthetic cells so bare they carry no DNA and can’t reproduce (nobody frets about calling those non-living); at the far end, still hypothetical, a cell built component by component that would want for nothing a natural cell has, and would therefore count as alive. SpudCell sits closer to that far end than anything before it. The report walked the spectrum with eight case studies, from cells that sniff out household hazards to ones designed to chew through contaminants at an EPA cleanup site.

Most of the hazards, Carr reckons, look familiar. They rhyme with the worries we already carry about genetically modified organisms: a novel cell might outcompete native species, tip an ecosystem off balance, or, in the wrong lab, edge toward something nastier. He adds a caveat that gets lost in scarier tellings: “presence doesn’t equal harm; just because something is in the environment doesn’t mean it’s causing a problem.”

The One Exception With a Fairy-Tale Name

There is, though, one category that made the committee sit up. Mirror life. The molecules of the living world have handedness, a lopsidedness like the difference between your left palm and your right, and nature committed early to just one orientation for its crucial kit, its DNA and proteins. Now picture a cell built entirely from the reflections. The trouble is our immune systems, honed over hundreds of millions of years against ordinary microbes, have never met such a thing and might fail to see it coming. A mirror bacterium could, some fear, spread with no evolved defences against it. A group of prominent scientists broke from the usual reassurances last year to call mirror life a hazard class all its own, and Carr’s committee agreed it sits apart.

What keeps a report like this honest is the stuff past the edge of the map. “Because this is still so very new, there’s much that we can’t predict yet,” Carr says, and he means it as a to-do list, not a shrug. His committee’s most insistent ask is almost humble: go and find out, while the field’s creations are still simple and safe enough to interrogate. Run the controlled lab study, then the careful field trial. How long does a scrap of synthetic DNA linger out there, and does anything else scavenge it? The committee also wants the sprawling US oversight system, carved up between the FDA, the EPA and the USDA, stitched together with an interagency working group, and the public treated as a real interlocutor rather than an audience to be soothed.

Adamala, for her part, is already thinking past the milestone toward the plumbing. Getting SpudCell to work meant flying collaborators in for hands-on demonstrations, which she doesn’t sugar-coat: “That’s not scalable.” So alongside the paper she and outside partners are launching Biotic, a public-benefit outfit meant to build shared, open infrastructure for the whole field. An infrastructure built privately, she warns, “just gives someone a toll booth.”

Consolidate those seven plasmids into one stable genome, add machinery, agree standards between labs, and the dream on the far horizon is a manufacturing platform that does chemistry industry can’t: drugs woven from amino acids evolution never tried, materials grown rather than synthesised. That green blob on a Minnesota bench is a long way from any of it. But it has already made the argument that the gap between what we can build and what we can name is only going to widen.

Frequently Asked Questions